SOP Maßnahmen bei Diarrhö unter Chemotherapie und zielgerichteter Therapie

[1]  R. Bose,et al.  Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Bardia,et al.  Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer , 2019, The New England journal of medicine.

[3]  A. V. van Kuilenburg,et al.  DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. , 2018, The Lancet. Oncology.

[4]  P. Bossi,et al.  Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  W. Allum,et al.  Guidance on the management of diarrhoea during cancer chemotherapy. , 2014, The Lancet. Oncology.

[6]  W. Voigt,et al.  Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management , 2010, Therapeutic advances in medical oncology.

[7]  U. Hofmann,et al.  Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Joensuu,et al.  Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study , 2007, British Journal of Cancer.

[9]  M. Gumus,et al.  The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients , 2004, International Journal of Colorectal Disease.

[10]  J. Ajani,et al.  Recommended guidelines for the treatment of cancer treatment-induced diarrhea. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Loeffler,et al.  Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  G. Vassal,et al.  Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.